<!DOCTYPE html>
<html>
    <head>
        <link rel="stylesheet" href="https://stackpath.bootstrapcdn.com/bootstrap/4.5.2/css/bootstrap.min.css" integrity="sha384-JcKb8q3iqJ61gNV9KGb8thSsNjpSL0n8PARn9HuZOnIxN0hoP+VmmDGMN5t9UJ0Z" crossorigin="anonymous">
        <link rel="stylesheet" href="flowchart-tree.css">
        
        <script src="d3.min.js" charset="utf-8"></script>
        <script src="script.js"></script>
        
    </head>
    <body class="container-sm" id="intro">
    
   <table class="table table-sm table-borderless">
        <thead>
            <tr>
                <td>Pathways Home</td>
                <td>Emergency</td>
                <td>ICU</td>
                <td>Inpatient</td>
                <td>Outpatient</td>
            </tr>
        </thead>
    </table>

    <row>
    <h3 style="color:#5bc0de">Pre-Cardiac Catheterization Anticoagulation Bridging Pathway (HUP)</h3>
    </row>
    
    <section>
    
    
       <!--Sidebar for Evidence-->
       <div class="d-none d-lg-block col-lg-2 bd-toc">
          <div class="sidenav"  style="color: #546E7A">
            <div class="card-body"><h6 class="card-title">Evidence</h6>
              <p style="text-align:left">
              <a href=""></a> <ion-icon name="open-outline"></ion-icon>
              </p>          
            </div>
            <div class="card-body"><h6 class="card-title"></h6>
                <p style="text-align:left; font-size:9px">
                <b>Posted:</b> Nov 2017 
                  <!--<br><b>Revised:</b> -->
                  <br><b>Team:</b> M. Julien, MD; H. Herrmann, MD; T. Hecht, MD; C. Domenico, PharmD; J. Harris
                </div> 
          </div></div>
    <!--<ul>-->
        <!--<span> Home<span>-->
        
        
                              
                              
          <ul class=tree>
            
              <!--<div class="card" style="width: 8rem; margin-top-4rem; padding:0">-->
              <!--<div class="card-body"><h6 class="card-subtitle">Goals and Metrics</h6>-->
              <!--</div></div>-->
              
              <!--<div class="card" style="width: 8rem; margin-top:0rem; padding:0">-->
              <!--<div class="card-body"><h6 class="card-subtitle">Patient Education</h6>-->
              <!--</div></div>-->
            
              <li><span>Pre-Cardiac Cath Anticoag Bridging Pathway (HUP)</span> 
                <ul>
                <li><span class="card" style="width:25rem"><div class="card-body" style="text-align: left">
                            <h5 class="card-title">Guiding Principles</h5>
                            <h6 class="card-subtitle mb-2 text-muted">High bleeding risk procedures (>1.5%) can result in intracranial, intraspinal, intraocular, retropertoneal, intrathoracic, or pericardial bleeding</h6>
                            <p style="margin-bottom:0px">Balance risk of bleeding vs Risk of thromboembolic events<br>Interval without anticoagulation therapy should be as short as possible.</p>
                            <p style="margin-bottom:0px"><br><i>*Refer to <b>CHADS2-VASc</b> Score for Afib patients</i></p>
                          </div></span>

                    
                         
                   <ul>     
                    <li><span class="card">
                          <div class="card-body" style="text-align:left">
                            <h5 class="card-title">Hold anticoagulant prior to procedure</h5>
                            <h6 class="card-subtitle mb-2 text-muted">Warfarin - 5 d + requires bridging for certain conditions <b>(right)</b></h6>
                            <h6 class="card-subtitle mb-2 text-muted">DOACs - variable</h6>
                            <p style="margin-bottom:0px">Refer to <b>Table </b>below</p>
                            </div></span>
                   
                   <ul> 
                    <li><span class="card">
                          <div class="card-body" style="text-align:left">
                            <h5 class="card-title">Resume anticoagulants post-procedure</h5>
                            <p>Warfarin: can resume same day hemostasis achieved.</p>
                            <p style="margin-bottom:0px">Bridging or DOACs should be resumed 12-24h after low-risk procedure (radial access)<br>OR 48-72 h for high risk procedure (femoral access)</p>
                     <li>       
                            <!--</div></span>-->
                   
                   <!--<ul>-->
                   <!--  <li>-->
                   <!--    <span class="card"><div class="card-body"><h5 class="card-title">Pharmacologic therapy</h5>-->
                   <!--    <p>Diuretic, Beta blocker, ACEi/ARB, Vasodilators, +/- IV iron</p></div></span>-->
                   <!--  <ul></ul></li>-->
                   <!--  <li>-->
                   <!--    <span class="card"><div class="card-body"><h5 class="card-title">Non-Pharmacologic therapy</h5>-->
                   <!--    <p>Nutrition, PT, Telemetry, Education, Sleep med, D/c planning</p></div></span>-->
                   <!--  </li>-->
                   <!--</ul>-->
                   
                   
                   </ul></ul></ul></ul></ul>
                   
                  
                   
                   
                   
                   <div class="container" style="margin-left:25rem; margin-top: -35rem;">
                     <span class="card" style="width:25rem; background-color:#ffffff">
                          <div class="card-body" style="text-align:left">
                            <h5 class="card-title">Conditions for which bridging should be considered</h5>
                            <h6 class="card-subtitle mb-2 text-muted">Each patient should be evaluated on a case-by-case basis</h6>
                             <h6 style="margin-bottom:0px; font-size:10px">
                                <ul><li>Mechanical aortic valves with valvular atrial fibrillation</li>
                                <li>Multiple mechanical valves</li>
                                <li>Mechanical mitral valve replacements</li>
                                <li>Venous thromboembolic event within 3mo</li>
                                <li>Prior thrombotic event when off anticoagulants for short duration</li>
                                <li>AF with prior CVA, thromboembolic event, cardiac thrombus or annual CVA risk > 8% (e.g. CHADS2 score <u>></u>4 OR CHADS2Vasc2 <u>></u>5</li>
                                <li>Severe thrombophilia</li>
                                <li>Mitral stenosis with atrial fibrillation or previous stroke</li>
                            </h6>
                            </div></span>
                    
                    
                    
                    <div class="card" style="width:25rem; margin:0">
                            <div class="card-body">
                            
                            <!--Warfarin Bridging Protocol  -->
                            
                            <h5 class="card-title" style="text-align: left">Warfarin: 5 Day hold + Bridging Protocol</h5>
                            <table class="table-sm table-bordered"  style="text-align: left">
                              <thead><tr><th scope="col" width="40px">Bridging instructions</th>
                                        <th scope="col" width="20px">CrCl < 15</th>
                                        <th scope="col" width="20px">15<u><</u> CrCl < 30</th>
                                        <th scope="col" width="20px" >30<u><</u> CrCl < 50</th>
                                        <th scope="col" width="20px">CrCl <u>></u>50</th>
                                        </tr>
                              </thead>
                              <tbody>
                                <tr><td>Hold Warfarin (Coumadin) <u>5 days</u> prior to procedure.<br><br>- Bridging therapy should begin 2 days AFTER last dose of warfarin was taken<br>- Bridging protocol for Afib, mechanical valve, or venous thromboembolism</td>
                                <td>Heparin infusion as an inpatient <br><br><u>Stopped 4 hrs prior to procedure.</u></td><td colspan="3">Enoxaparin (Lovenox) 1mg/kg subcutaneously every 12 hrs<br><br> <u>Last dose > 24h prior to procedure</u></td></tr>
                          
                              </table>
                              <p></p>
                          
                            <!--DOACs -->
                            
                            <h5 class="card-title" style="text-align: left">DOACs: Days to hold, by Agent</h5>
                            <table class="table-sm table-bordered"  style="text-align: left">
                              <thead><tr><th scope="col" colspan="2">Name</th>
                                        <th scope="col" width="20px">CrCl < 15</th>
                                        <th scope="col" width="20px">15<u><</u> CrCl < 30</th>
                                        <th scope="col" width="20px" >30<u><</u> CrCl < 50</th>
                                        <th scope="col" width="20px">CrCl <u>></u>50</th>
                                        <!--<th scope="col"></th>-->
                                        <!--<th scope="col">Treatment Recommended</th>-->
                                        </tr>
                              </thead>
                              <tbody>
                                <tr><td rowspan="4" width="20px">Direct Oral Anticoagulants (DOACs)</td>
                                <td width="30px">Dabigatran</td><td rowspan="4">*Unknown. Consider changing from a DOAC to warfarin pre-operatively in patients with CrCl < 15 mL/min in order to allow for a more predictable hold duration prior to OR.</td><td>6 d</td><td>4 d</td><td>3 d</td></tr>
                                <tr><td>Rivaroxaban**</td><td>2-3 d</td><td>2 d</td><td>2 d</td></tr>
                                <tr><td>Apixaban**</td><td>4 d</td><td>4 d</td><td>3 d</td></tr>
                                <tr><td>Edoxaban</td><td>4 d</td><td>3 d</td><td>2 d</td></tr>
                                </tbody>
                            </table>
                            <p style="font-size:9px; text-align:left">**If on Rivaroxaban 15mg or Apixaban 10mg BID during first 1-3 wks of treatment for acute PE/DVT, hold time may need to be longer.</p>
                          
                            </div></div>  
                            
                          <!--</div>-->
                   </ul></ul></ul></ul></ul>
                   
                   
     <row style="height:20rem"></row>
   
  </section>
    </body>
</html>             
                      